



Achillion Pharmaceuticals (USA): Constituent Deletion

Changes in FTSE RAFI™ Index Series

27 January 2020

Subject to the completion of the cash acquisition of Achillion Pharmaceuticals (USA, constituent) by Alexion Pharmaceuticals Inc, please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI US 1500 Mid Small Index	30 January 2020
FTSE RAFI US 1500 Mid Small Index - QSR	30 January 2020

*In the absence of an active market, Achillion Pharmaceuticals will be removed at the cash acquisition terms of \$6.30 per share held.

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia	+1800 653 680
Hong Kong	+852 2164 3333
Japan	+81 3 4563 6346
London	+44 (0) 20 7866 1810
New York	+1866 551 0617

Alternatively please visit our website at www.ftserussell.com

[Terms of Use](#) | Copyright © 2020 FTSE Russell